 |
23 Diseases |  |
10 Trials |
|
10 Trials |  |
138 News |  |
| «123 |
- letrozole / Generic mfg.
Enrollment change: Use of High Cost Monitoring During Letrozole Ovulation Induction (clinicaltrials.gov) - Jun 12, 2014
P4, N=21, Completed, Sponsor: University of Michigan
N=400 --> 21
- letrozole / Generic mfg.
Trial completion: Use of High Cost Monitoring During Letrozole Ovulation Induction (clinicaltrials.gov) - Jun 12, 2014
P4, N=21, Completed, Sponsor: University of Michigan
N=400 --> 21 Active, not recruiting --> Completed
- ||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial initiation date: Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) - Apr 17, 2014
P3, N=946, Ongoing, Sponsor: Merck KGaA`Merk KGaA
Active, not recruiting --> Completed Initiation date: Jan 2014 --> Dec 2013
- || Ovidrel (choriogonadotropin alfa) / EMD Serono, Orgalutran (ganirelix acetate) / Organon
New P3 trial, Preclinical: Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response. (clinicaltrials.gov) - Apr 17, 2014
P3, N=232, Recruiting, Sponsor: Instituto de Investigacion Sanitaria La Fe
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial termination: The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes (clinicaltrials.gov) - Feb 21, 2014
P4, N=400, Terminated, Sponsor: Antalya IVF
Initiation date: Jan 2014 --> Dec 2013 Recruiting --> Terminated; treatment strategy changed
- | Ovidrel (choriogonadotropin alfa) / EMD Serono
New P4 trial: Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures (clinicaltrials.gov) - Jan 27, 2014
P4, N=100, Not yet recruiting, Sponsor: Rambam Health Care Campus
- |||||||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
New P3 trial: Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) - Jan 26, 2014
P3, N=946, Ongoing, Sponsor: Merck KGaA`Merk KGaA
- Ovidrel (choriogonadotropin alfa) / EMD Serono
New P4 trial: The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes (clinicaltrials.gov) - Nov 6, 2013
P4, N=400, Terminated, Sponsor: Antalya IVF
- ||||||| DA-3803 (choriogonadotropin alfa biosimilar) - Dong / A
Trial completion: Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel (clinicaltrials.gov) - Aug 11, 2013
P3, N=180, Completed, Sponsor: Dong-A Pharmaceutical Co., Ltd.
Recruiting --> Terminated; treatment strategy changed Recruiting --> Completed
- ||||||| Cetrotide (cetrorelix) / EMD Serono
Trial completion: ATTAC-PCO: Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Jul 1, 2013
P3, N=136, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Active, not recruiting --> Completed
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial initiation date: Luveris (clinicaltrials.gov) - May 21, 2013
P4, N=11, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Completed Initiation date: Oct 2005 --> Mar 2006
- | DA-3803 (choriogonadotropin alfa biosimilar) - Dong / A
New P1 trial: A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803 (clinicaltrials.gov) - May 8, 2013
P1, N=27, Completed, Sponsor: Dong-A Pharmaceutical Co., Ltd.
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open: Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Hospital
Initiation date: Oct 2005 --> Mar 2006 Not yet recruiting --> Recruiting
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion: Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Jan 27, 2013
P3, N=25, Completed, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| DA-3803 (choriogonadotropin alfa biosimilar) - Dong / A
New P3 trial: Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel (clinicaltrials.gov) - Oct 29, 2012
P3, N=180, Completed, Sponsor: Dong-A Pharmaceutical Co., Ltd.
- ||||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion: PERSIST: PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (clinicaltrials.gov) - Sep 30, 2012
P3, N=202, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Recruiting --> Completed
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Preclinical, Trial initiation date: EXpression PRofile Endometrium Samples Study (clinicaltrials.gov) - Jul 2, 2012
P4, N=27, Terminated, Sponsor: Merck KGaA
Recruiting --> Completed Initiation date: Dec 2007 --> Aug 2008
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial termination: Luveris (clinicaltrials.gov) - Jun 11, 2012
P4, N=11, Terminated, Sponsor: EMD Serono
Initiation date: Dec 2007 --> Aug 2008 Recruiting --> Terminated; Please see "Purpose" statement
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment change: Luveris (clinicaltrials.gov) - Jun 11, 2012
P4, N=11, Terminated, Sponsor: EMD Serono
Recruiting --> Terminated; Please see "Purpose" statement N=234 --> 11
- Ovidrel (choriogonadotropin alfa) / EMD Serono, Vagifem (estradiol) / Novo Nordisk, Estrofem (estradiol oral) / Novo Nordisk
Enrollment open: The Luteal Phase After GnRHa Trigger - a Proof of Concept Study (clinicaltrials.gov) - May 25, 2012
P4, N=180, Recruiting, Sponsor: Regionshospitalet Viborg, Skive
N=234 --> 11 Not yet recruiting --> Recruiting
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Vagifem (estradiol) / Novo Nordisk, Estrofem (estradiol oral) / Novo Nordisk
New P4 trial: The Luteal Phase After GnRHa Trigger - a Proof of Concept Study (clinicaltrials.gov) - Jan 3, 2012
P4, N=180, Recruiting, Sponsor: Regionshospitalet Viborg, Skive
- Epogen (epoetin alfa) / Amgen
Trial withdrawal: REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (clinicaltrials.gov) - Sep 1, 2011
P2b, N=30, Withdrawn, Sponsor: Stem Cell Therapeutics Corp.
Not yet recruiting --> Recruiting Terminated --> Withdrawn